Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)

NICE is unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy. This is because Boehringer Ingelheim did not provide an evidence submission.

Last reviewed: 24 May 2017

Next review: We will review this decision if the company decides to make a submission.